Professor Dr. med. Thomas Seufferlein appointed Chair of new Scientific Advisory Board (SAB) composed of leaders with deep expertise in the clinical oncology field New SAB to complement...
Immodulon Further Strengthens Leadership Team with the Appointments of Richard Couch as Chief Technology Officer and Owen Vaughan as Chief Regulatory Officer Richard Couch, formerly at Celgene,...
London, UK-based Immodulon has teamed up with Lisbon, Portugal-based non-profit organisation the Champalimaud Foundation to research and examine the potential use of the experimental treatment IMM-101 in combination with other therapies in 'difficult to treat' cancers.